CURTANA

Curtana is advancing a novel small molecule therapy, CT-179, which has been shown to significantly prolong survival in relevant animal models. The target is Olig2, a cancer stem cell-associated transcription factor that is critical for tumor initiation and growth. CT-179 will enter clinical development in Q2 2022... Curtana Pharmaceuticals was founded on a mission to develop the first truly targeted therapies for the treatment of the most aggressive types of brain cancers in adults and children. The company's drug development program is based on the pioneering research of Dr. Santosh Kesari, who is currently the Chairman of the Department of Translational Neuro-oncology and Neuro-therapeutics at the John Wayne Cancer Institute in Santa Monica, CA... Curtana's senior leadership brings years of experience in the pharmaceutical industry, with extensive backgrounds in the development of new molecular entities for the treatment of cancer as well as CNS disorders.

Primary location: Austin United States